We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Could Identify Which Patients Need Antibiotics

By LabMedica International staff writers
Posted on 31 Jan 2016
Print article
Image: Molecular surface of the capsid of human rhinovirus, one of the viruses which cause acute respiratory infections (Photo courtesy of A. J. Cann).
Image: Molecular surface of the capsid of human rhinovirus, one of the viruses which cause acute respiratory infections (Photo courtesy of A. J. Cann).
Acute respiratory infections caused by bacterial or viral pathogens are among the most common reasons for seeking medical car and despite improvements in pathogen-based diagnostics, most patients receive inappropriate antibiotics.

Misuse of antibiotics is a key contributor to antibiotic resistance; if a patient takes antibiotics for a viral infection, the drug will still attack bacteria in the body, but it will attack healthy or beneficial bacteria. This can cause antibiotic-resistant properties that can be passed on to other bacteria.

Scientists at Duke University (Durham, NC, USA) and their colleagues investigated whether host response biomarkers offer an alternative diagnostic approach to direct antimicrobial use. The observational cohort study determined whether host gene expression patterns discriminate noninfectious from infectious illness and bacterial from viral causes of acute respiratory infection in the acute care setting. Peripheral whole blood gene expression from 273 subjects with community-onset acute respiratory infection (ARI) or noninfectious illness, as well as 44 healthy controls, was measured using microarrays.

By measuring patients' gene expression profiles from blood samples, the team found they could use the previously identified gene signatures to correctly identify patients with influenza viruses, rhinovirus, various streptococci bacteria and other common infections with 87% accuracy. This Overall accuracy from 238 of 273 subjects was concordant with clinical adjudication, which was more accurate than procalcitonin (78%), and three published classifiers of bacterial versus viral infection (78 to 83%). The classifiers developed were externally validated in five publicly available data sets. A sixth publicly available data set included 25 patients with co-identification of bacterial and viral pathogens.

The authors concluded that by applying the ARI classifiers they could define four distinct groups: a host response to bacterial ARI, viral ARI, coinfection, and neither a bacterial nor a viral response. These findings create an opportunity to develop and use host gene expression classifiers as diagnostic platforms to combat inappropriate antibiotic use and emerging antibiotic resistance. They note that there is one major limitation, however as at present as it takes around 10 hours to assess a patient's gene expression profile, but the team says they are in the process of working with developers to create a one hour test that can be used by clinicians.

Christopher Woods, MD, MPH, a professor of medicine and senior author of the study, said, “The ideal scenario, should this test ultimately be approved for broad use, is you would go to the doctor's office and receive your results by the time you meet with your provider. We are working to develop a test that could be run in most clinical labs on existing equipment. We believe this could have a real impact on the appropriate use of antibiotics and guide the use of antiviral treatments in the future.” The study was published on January 20, 2016, in the journal Science Translational Medicine.

Related Links:

Duke University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.